Table 1 Characteristics of the included studies

Attia, 1998 [17]

7 weeks

Clinical

Restricting/Binge-purge

1. AD

73 (IBW)

15

26

Fluoxetine 60 mg

Inpatient

1. Individual therapy

1.% IBW

27%

2. Placebo

72 (IBW)

16

2. Group therapy

2. Change in % IBW/day

25%

3. Family therapy

4. Behavior therapy

5. Caloric repletion

Attia, 2011 [18]

8 weeks

Clinical

Restricting/Binge-purge

1. AP

16.7

11 12 (1 male)

27.7

Olanzapine

Outpatient

1. BMI

26%

2. Placebo

17.4

2.5 mg

25%

5 mg

10 mg

Bissada, 2008 [19]

10 weeks

Clinical

Restricting/Binge-purge

1. AP

16.39

18

29.7

Olanzapine

Day hospital

1. Meal supervision

1. BMI

14%

2. Placebo

15.93

16

23.6

2.5 mg

2. Group therapy

28%

5 mg

7.5 mg

10 mg

Brambilla 2007a [20]

3 months

Clinical

Unknown

1. AP

15.5

15

23.7

Olanzapine

Outpatient

1. CBT

1. BMI

14%

2. Placebo

15.8

15

26.3

2.5 mg

5 mg

Brambilla 2007b [21]

3 months

Clinical

Restricting/Binge-purge

1. AP

15.7

10

23

Olanzapine

Outpatient

1. CBT

1. BMI

n.m.

2. Placebo

16.3

10

2.5 mg

2. Nutritional rehabilitation

5 mg

Di Vasta 2012 [22]

18 months

Clinical

Restricting/Binge-purge

1. H

18.1

47

18.1

Dehydroepiandrosterone

Outpatient

1. Routine care = medical, nutritional, psychological monitoring

1. Kg

34%

2. Placebo

47

50 mg

2. BMI

38%

3. Lean mass

4. Fat mass

1st Author, Year

Length of RCT

Recruitment

Anorexia type

Treatment conditions

Baseline mean weight ^a

N

Age

Type

Setting

Adjunctive treatments

Weight outcome measures

Drop-out

Fazeli 2010 [23]

12 weeks

Community and clinical

Restricting/Binge-purge

1. GH

17.4

10

28

Nutropin

Outpatient

1. Kg ch.

10%

2. Placebo

17.2

11

29.2

15 mg

2.%IBW ch.

18%

3.% lean ch.

4. Lean ch.

5. Extremity lean ch.

6.% fat ch.

7. Fat mass ch.

8. Trunk fat ch.

9. Extremity fat ch.

Grinspoon 1996 [24]

9 months

Clinical

Restricting/ Binge-purge

1. GH 30 mg

16.3

11

23

Insulin-like growth factor I

Inpatient

1.%IBW

0

2. GH 100 mg

17

11

30 or 100 mg

2. BMI

19%

3. Placebo

15.6

11

9%

Grinspoon 2002 [25]

6 days

Clinical

Restricting/ Binge-purge

1. GH + H

35 kg

16

24.2

Recombinant human IGF-I + Ovcon

Outpatient

1. Calcium

1.Kg

12%

2. GH

35 kg

14

23

2x 30 mg

2. Multivitamins

2. Lean body mass (kg)

28%

3. Placebo + GH

35.4 kg

15

27.6

0

3. Placebo

32.3 kg

15

26.3

7%

Halmi 1986 [26]

32-45 days

Clinical

Restricting/ Binge-purge

1. AH

79 (IBW)

23

20.56

Amitryptyline

Inpatient

1. Days to target weight

n.m.

2. AD

77 (IBW)

24

160 mg (max)

2. Average kg gain/day

3. Placebo

75 (IBW)

25

Hill 2000 [27]

28 days

Clinical

Restricting/ Binge-purge

1.GH

14

7

14.5

Recombinant human growth hormone

Inpatient

1. Standard treatment

1. Average kg gain/day

n.m.

2. Placebo

15

8 (1 male)

15

0.05 mg

1st Author, Year

Length of RCT

Recruitment

Anorexia type

Treatment conditions

Baseline mean weight ^a

N

Age

Type

Setting

Adjunctive treatments

Weight outcome measures

Drop-out

Kafantaris 2011 [28]

10 weeks

Clinical

Restricting

1. AP

16.9

10

17.1

Olanzapine

Outpatient and inpatient

1. Individual medication

1. BMI

30%

2. Placebo

16

10

2.5 mg

2. Psychotherapy

2.%MBW

20%

5 mg

3. Family therapy

7.5 mg

4. Nutritional therapy

10 mg

Lacey 1980 [29]

n.m.

Clinical

Restricting/ Binge-purge

1. AD

40.6 (kg)

8

n.m.

Clomipramine

Inpatient

1. Individual psychotherapy

1. Kg

25%

2. Placebo

37.7 (kg)

8

50 mg

2. Caloric repletion

2. Mean kg gain

12%

3. Rate kg gain/day

Miller 2011 [30]

12 months

Community and clinical

Restricting/ Binge-purge

1. OM/ H

17.8

20

25.2

Risedronate/Testosterone

Outpatient

1. Kg

23%

2. OM

17.6

20

25.3

35 mg/ 150 mg

2. Lean body mass

3. H

17.5

19

27.1

4. Placebo

17.9

18

26.9

Misra 2011 [31]

18 months

Community and clinical

Restricting/ Binge-purge

1. H

17.4

55

16.5

Fysiologic estrogen replacement

Outpatient

1. Behavior therapy

1. Kg

56%

2. Placebo

55

100 mg

2. BMI

54%

3. Fat mass

4. Lean mass

Strokosch 2006 [32]

13x28 days

Clinical

Restricting/ Binge-purge

1. H

17.9

61

15.2

Norgestimate/ Ethinyl Estradiol

Outpatient

1. Kg

34%

2. Placebo

17.6

62

15.1

180-250 mg/ 35 mg

2. BMI

21%

Vandereycken 1984 [33]

2x3 weeks

Clinical

Restricting/ Binge-purge

1. AP

40.4 (kg)

9

23.2

Sulpiride

Inpatient

1. Uniform therapeutic programme

1. Daily g change

n.m.

2. Placebo

38.3 (kg)

9

23.7

300 or 400 mg

Walsh 2006 [34]

1 year

Community and clinical

Restricting/ Binge-purge

1. AD

15.4

49

22.4

Fluoxetine

Outpatient

1. CBT

1. BMI

57%

2. Placebo

44

24.2

20 mg to 60 mg

2. Family therapy

57%

3. Medication monitoring